Black Diamond Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Black Diamond Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q3 2024.
  • Black Diamond Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$18.1M, a 24.5% increase year-over-year.
  • Black Diamond Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$81.4M, a 6.97% increase year-over-year.
  • Black Diamond Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$86.5M, a 6.86% increase from 2022.
  • Black Diamond Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$92.8M, a 26.8% increase from 2021.
  • Black Diamond Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$127M, a 82.4% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$81.4M -$18.1M +$5.88M +24.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$87.2M -$22.1M -$2.1M -10.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$85.1M -$20.2M +$1.32M +6.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$86.5M -$20.9M +$997K +4.56% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-12
Q3 2023 -$87.5M -$24M -$1.89M -8.53% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$85.6M -$20M +$3.14M +13.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$88.7M -$21.6M +$4.12M +16% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$92.8M -$21.9M +$4.23M +16.2% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-12
Q3 2022 -$97.1M -$22.1M +$13.2M +37.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$110M -$23.2M +$11.5M +33.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$122M -$25.7M +$5.03M +16.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 -$127M -$26.1M -$2.9M -12.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 -$124M -$35.4M -$16.9M -91.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$107M -$34.7M -$19.7M -131% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$87.4M -$30.7M -$17.8M -138% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 -$69.6M -$23.2M -$12.8M -124% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-25
Q3 2020 -$56.7M -$18.5M -$10.3M -127% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$46.4M -$15M -$8.03M -115% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$38.4M -$12.9M -$9.04M -235% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 -$29.3M -$10.3M -$7.3M -240% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 -$22M -$8.15M -$5.81M -248% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-25
Q2 2019 -$16.2M -$7M -$5.09M -266% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-25
Q1 2019 -$11.1M -$3.84M -$2.24M -139% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-25
Q4 2018 -$8.9M -$3.05M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-24
Q3 2018 -$2.34M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-24
Q2 2018 -$1.91M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-24
Q1 2018 -$1.61M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.